These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 17461853)

  • 1. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
    Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
    Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
    J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
    Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
    AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
    Macías J; Melguizo I; Fernández-Rivera FJ; García-García A; Mira JA; Ramos AJ; Rivera JM; Pineda JA
    Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):775-81. PubMed ID: 12461586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population.
    Ormaasen V; Sandvik L; Dudman SG; Bruun JN
    Scand J Infect Dis; 2007; 39(1):51-7. PubMed ID: 17366013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
    Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
    Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.
    Ferreros I; Lumbreras B; Hurtado I; Pérez-Hoyos S; Hernández-Aguado I
    Addiction; 2008 Apr; 103(4):651-9. PubMed ID: 18339110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of HIV infection in the post-HAART era among a cohort of HIV+ Greek haemophilia patients.
    Katsarou O; Touloumi G; Antoniou A; Kouramba A; Hatzakis A; Karafoulidou A
    Haemophilia; 2005 Jul; 11(4):360-5. PubMed ID: 16011588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
    Herida M; Mary-Krause M; Kaphan R; Cadranel J; Poizot-Martin I; Rabaud C; Plaisance N; Tissot-Dupont H; Boue F; Lang JM; Costagliola D
    J Clin Oncol; 2003 Sep; 21(18):3447-53. PubMed ID: 12972519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the incidence and aetiology of fever of unknown origin (FUO), and survival in HIV-infected patients after HAART (Highly Active Antiretroviral Therapy).
    Abellán-Martínez J; Guerra-Vales JM; Fernández-Cotarelo MJ; González-Alegre MT
    Eur J Intern Med; 2009 Sep; 20(5):474-7. PubMed ID: 19712847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).
    Guillén S; García San Miguel L; Resino S; Bellón JM; González I; Jiménez de Ory S; Muñoz-Fernández MA; Navarro ML; Gurbindo MD; de José MI; Mellado MJ; Martín-Fontelos P; Gonzalez-Tomé MI; Martinez J; Beceiro J; Roa MA; Ramos JT;
    HIV Med; 2010 Apr; 11(4):245-52. PubMed ID: 20050937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in perimortal conditions and mortality rates among HIV-infected patients.
    Hooshyar D; Hanson DL; Wolfe M; Selik RM; Buskin SE; McNaghten AD
    AIDS; 2007 Oct; 21(15):2093-100. PubMed ID: 17885300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002.
    Martín-Carbonero L; Sánchez-Somolinos M; García-Samaniego J; Núñez MJ; Valencia ME; González-Lahoz J; Soriano V
    J Viral Hepat; 2006 Dec; 13(12):851-7. PubMed ID: 17109686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
    Gingues S; Gill MJ
    HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.